JP2022511881A - 操作されたフラジェリン由来の組成物と用途 - Google Patents
操作されたフラジェリン由来の組成物と用途 Download PDFInfo
- Publication number
- JP2022511881A JP2022511881A JP2021532369A JP2021532369A JP2022511881A JP 2022511881 A JP2022511881 A JP 2022511881A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2021532369 A JP2021532369 A JP 2021532369A JP 2022511881 A JP2022511881 A JP 2022511881A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- flagellin
- hydrophilic
- residue
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776507P | 2018-12-07 | 2018-12-07 | |
| US62/776,507 | 2018-12-07 | ||
| PCT/US2019/064954 WO2020118192A1 (en) | 2018-12-07 | 2019-12-06 | Engineered flagellin-derived compositions and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511881A true JP2022511881A (ja) | 2022-02-01 |
| JP2022511881A5 JP2022511881A5 (cg-RX-API-DMAC7.html) | 2022-12-14 |
Family
ID=70974397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532369A Pending JP2022511881A (ja) | 2018-12-07 | 2019-12-06 | 操作されたフラジェリン由来の組成物と用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220024991A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3890769A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022511881A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210111770A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113382742A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019392903A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122067A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191610A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL283757A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020118192A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| CN119522108A (zh) * | 2022-06-01 | 2025-02-25 | 弗莱格生物公司 | Rna佐剂、其方法和用途 |
| KR102896818B1 (ko) * | 2022-10-19 | 2025-12-08 | 전남대학교 산학협력단 | Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용 |
| KR20240081501A (ko) * | 2022-11-14 | 2024-06-10 | 전남대학교산학협력단 | 암의 치료용 면역증강 살모넬라 균주 및 이의 용도 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524890A (ja) * | 2011-05-21 | 2014-09-25 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
| JP2016512251A (ja) * | 2013-03-14 | 2016-04-25 | リサーチ コーポレーション テクノロジーズ インコーポレイテッド | サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子 |
| JP2017523184A (ja) * | 2014-07-30 | 2017-08-17 | クリーブランド バイオラブズ,インコーポレイテッド | フラジェリン組成物および使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121734B1 (en) * | 2007-02-09 | 2013-05-08 | Industry Foundation of Chonam National University | Modified flagellin improved toll-like receptor 5 stimulating activity |
-
2019
- 2019-12-06 EA EA202191610A patent/EA202191610A1/ru unknown
- 2019-12-06 EP EP19892798.0A patent/EP3890769A4/en not_active Withdrawn
- 2019-12-06 CN CN201980090594.0A patent/CN113382742A/zh active Pending
- 2019-12-06 US US17/299,373 patent/US20220024991A1/en not_active Abandoned
- 2019-12-06 CA CA3122067A patent/CA3122067A1/en active Pending
- 2019-12-06 WO PCT/US2019/064954 patent/WO2020118192A1/en not_active Ceased
- 2019-12-06 JP JP2021532369A patent/JP2022511881A/ja active Pending
- 2019-12-06 AU AU2019392903A patent/AU2019392903A1/en not_active Abandoned
- 2019-12-06 KR KR1020217021065A patent/KR20210111770A/ko not_active Ceased
-
2021
- 2021-06-06 IL IL283757A patent/IL283757A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524890A (ja) * | 2011-05-21 | 2014-09-25 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
| JP2016512251A (ja) * | 2013-03-14 | 2016-04-25 | リサーチ コーポレーション テクノロジーズ インコーポレイテッド | サルシン及び他の関連する真菌リボトキシンに由来するリボトキシン分子 |
| JP2017523184A (ja) * | 2014-07-30 | 2017-08-17 | クリーブランド バイオラブズ,インコーポレイテッド | フラジェリン組成物および使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122067A1 (en) | 2020-06-11 |
| US20220024991A1 (en) | 2022-01-27 |
| IL283757A (en) | 2021-07-29 |
| EA202191610A1 (ru) | 2021-10-25 |
| CN113382742A (zh) | 2021-09-10 |
| AU2019392903A1 (en) | 2021-06-24 |
| EP3890769A4 (en) | 2022-11-23 |
| EP3890769A1 (en) | 2021-10-13 |
| KR20210111770A (ko) | 2021-09-13 |
| WO2020118192A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11034733B2 (en) | Flagellin compositions and uses | |
| KR20220068240A (ko) | 암 치료를 위한 암 요법과 사이토카인 조절 요법의 조합 | |
| JP7402691B2 (ja) | 抗cd25抗体薬物複合体による併用療法 | |
| US10196435B2 (en) | OX40L fusion protein for the immunotherapy of tumors of veterinary animals | |
| JP2021502808A (ja) | がんの処置におけるcar−t細胞またはcar−nk細胞を用いるlilrb4のターゲティング法 | |
| US20220024991A1 (en) | Engineered flagellin-derived compositions and uses | |
| TW202233249A (zh) | 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療 | |
| JP2020517629A5 (cg-RX-API-DMAC7.html) | ||
| JP2022522775A (ja) | Lilrb4結合抗体およびその使用方法 | |
| JP7740994B2 (ja) | 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療 | |
| RS53327B (sr) | Monoklonsko antitelo na cd44, za korišćenje u lečenju karcinoma skvamoznih ćelija glave i vrata | |
| WO2016014899A1 (en) | Flagellin derivatives and uses | |
| US20250145715A1 (en) | B7-h3 targeting fusion proteins and methods of use thereof | |
| JP7590083B2 (ja) | 併用療法 | |
| JP2025179057A (ja) | 併用療法のための患者の選択 | |
| EP4031655A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
| US10912791B2 (en) | Compositions comprising antisense-encoded erythropoietin receptor and use thereof | |
| HK1237803A1 (en) | Flagellin compositions and uses | |
| HK1237803B (en) | Flagellin compositions and uses | |
| Wagner | Investigation of a Novel Small Molecule TRAIL Inducer, ONC201: Pre-clinical Anti-cancer Efficacy, Anti-metastasis Effects, Tumor Immunity; and the Structure-activity Relationships (SAR) and Mechanism of Action of Potential Analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221206 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240730 |